Barely Significant

Excerpts

3,685 sentences · 1 filter applied

In a population similar to that of our study consisting of 54 patients undergoing induction chemotherapy based on immunomodulatory drugs (IMIDs) and proteasome inhibitors (PIs), followed by ASCT, the IMAJEM study showed a trend to a significant prognostic impact of pre-transplant PET/CT on PFS [ 6 ].
highly significantqualifiedgold
The eight-year probability of overall survival was 34 ± 2% with highly significant differences according to NHL subtypes: 28 ± 3% for 254 Burkitt lymphoma/leukemia, 50 ± 6% for 98 diffuse large B-cell lymphomas, 57 ± 8% for 41 primary mediastinal large B-cell lymphomas, 27 ± 3% for 177 T-lymphoblastic lymphomas, 52 ± 10% for 34 precursor-B-cell lymphoblastic lymphomas and 30 ± 9% for 35 patients with rare NHL subtypes.
While the Kaplan–Meier survival curves still demonstrated significantly better overall survival and disease-free survival for the “T3 single” group ( Supplementary Figures S1–S3 ), the difference in cancer-specific survival became less pronounced, although the curves still showed a trend towards better survival in the “T3 single” group.
We would emphasize that this observation should be interpreted with great care because the patients are few and the difference reached only borderline significance, but previous studies also suggest that ATRA therapy is less effective in patients with NPM1 wt [ 91 ].
Patients with high PD-L1 expression on IC showed a trend for improved survival as assessed by IC area 25% alone ( Figure 2 D; not significant in multivariable survival models) and significantly improved DSS (5-year DSS rate: 61%; HR mult = 0.44 [95%-CI = 0.27–0.72]) and DFS (5-year DFS rate: 58%; HR mult = 0.42 [95%-CI = 0.26–0.68]) as assessed by Ventana IC5% ( Figure 2 E).
In the quantitative studies, a notable trend emerged, with nine studies combining two EORTC instruments: the generic EORTC QLQ-C30 and the tumor-specific EORTC QLQ-GI.NET21, which focuses on muscle and/or bone pain, endocrine and gastrointestinal symptoms, and treatment-related effects ( Supplementary Table S2.4 ).